Indication
Cholinesterase inhibitors toxicity
Cholinesterase inhibitors toxicity is an acute or subacute toxidrome resulting from the pharmacological overdose of acetylcholinesterase-inhibiting medications or toxic exposure to organophosphates and carbamates. Read more about Cholinesterase inhibitors toxicity
26 drugs 25 manufacturers
Drugs that treat it
Common Cholinesterase inhibitors toxicity therapies.
ATROPINE SULFATE (atropine sulfate in 0.9 % sodium chloride)
ATROPINE SULFATE (atropine sulfate in 0.9 % sodium chloride)
ATROPINE SULFATE
ATROPINE SULFATE
ATROPINE SULFATE
HYOSCYAMINE SULFATE
ATROPINE SULFATE
ATROPINE SULFATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonCholinesterase inhibitors toxicity is an acute or subacute toxidrome resulting from the pharmacological overdose of acetylcholinesterase-inhibiting medications or toxic exposure to organophosphates and carbamates.
This pathological state affects the central, autonomic, and somatic nervous systems across pediatric and adult populations, most frequently arising in patients treated for myasthenia gravis, Alzheimer disease, or via accidental or intentional poisonings.
Pathophysiologically, the arrest of acetylcholinesterase activity prevents the normal enzymatic degradation of acetylcholine, causing massive neurotransmitter accumulation at synaptic junctions.
Clinically, this hypercholinergic state manifests as excessive muscarinic activation producing severe secretions, miosis, bronchospasm, and bradycardia; nicotinic overstimulation causing muscle fasciculations, weakness, and flaccid paralysis; and central nervous system disturbances including agitation, seizures, and respiratory failure.
- nih.gov
Cholinesterase inhibitors toxicity is an acute or subacute toxidrome resulting from the pharmacological overdose of acetylcholinesterase-inhibiting medications or toxic exposure to organophosphates and carbamates This pathological state affects the central, autonomic, and somatic nervous systems across pediatric and adult populations, most frequently arising in patients treated for myasthenia gravis, Alzheimer disease, or via accidental or intentional poisonings Pathophysiologically, the arrest ...
- nih.gov
Cholinesterase inhibitors toxicity is an acute or subacute toxidrome resulting from the pharmacological overdose of acetylcholinesterase-inhibiting medications or toxic exposure to organophosphates and carbamates Clinically, this hypercholinergic state manifests as excessive muscarinic activation producing severe secretions, miosis, bronchospasm, and bradycardia; nicotinic overstimulation causing muscle fasciculations, weakness, and flaccid paralysis; and central nervous system disturbances incl...
- nih.gov
This pathological state affects the central, autonomic, and somatic nervous systems across pediatric and adult populations, most frequently arising in patients treated for myasthenia gravis, Alzheimer disease, or via accidental or intentional poisonings
- nih.gov
This pathological state affects the central, autonomic, and somatic nervous systems across pediatric and adult populations, most frequently arising in patients treated for myasthenia gravis, Alzheimer disease, or via accidental or intentional poisonings
- nih.gov
Pathophysiologically, the arrest of acetylcholinesterase activity prevents the normal enzymatic degradation of acetylcholine, causing massive neurotransmitter accumulation at synaptic junctions
- nih.gov
Clinically, this hypercholinergic state manifests as excessive muscarinic activation producing severe secretions, miosis, bronchospasm, and bradycardia; nicotinic overstimulation causing muscle fasciculations, weakness, and flaccid paralysis; and central nervous system disturbances including agitation, seizures, and respiratory failure
Personalize your experience
Follow Cholinesterase inhibitors toxicity and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.